Latest Protein kinase inhibitor Stories
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S.
Phase III data for lenvatinib to be presented at ASCO WOODCLIFF LAKE, N.J., May 31, 2014 /PRNewswire/ -- Eisai Inc.
Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex,
-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29,
The Majority of Non-Prescribers Anticipate Prescribing Gilotrif Within the Next Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/
Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"),
Joint Publication Identifies Clinical Kinase Inhibitors that Potently Cross React with Bromodomain Epigenetic Reader Proteins OXFORD, United Kingdom and FREMONT, Calif., March 5, 2014
- A serpent whose bite was fabled to produce intense thirst.